NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among […]
Shares of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) have been given a consensus rating of “Moderate Buy” by the eight ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) – B. Riley lowered their Q2 2023 earnings per share estimates for NGM Biopharmaceuticals in a research report issued on Thursday, May 11th. B. Riley analyst M. Mamtani now forecasts that the company will post earnings per share of ($0.51) for the quarter, down from their prior estimate […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target […]